Leerink Partnrs Analysts Raise Earnings Estimates for ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a report issued on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($0.32) per share for the quarter, up from their previous estimate of ($0.54). The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($3.40) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals' Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($2.14) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97).

Other equities research analysts have also recently issued reports about the stock. StockNews.com raised shares of Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. Piper Sandler cut their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. B. Riley reissued a "buy" rating and set a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $41.44.

Arrowhead Pharmaceuticals Stock Up 4.4 %

ARWR traded up $0.84 during trading on Thursday, hitting $19.95. The company had a trading volume of 930,578 shares, compared to its average volume of 2,631,224. The company has a market capitalization of $2.50 billion, a PE ratio of -3.97 and a beta of 0.95. Arrowhead Pharmaceuticals has a one year low of $17.05 and a one year high of $36.72. The firm's 50-day moving average price is $20.00 and its 200 day moving average price is $21.05. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 32,729 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $648,688.78. Following the transaction, the insider now owns 272,122 shares in the company, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the company's stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the completion of the transaction, the director now owns 36,740 shares in the company, valued at approximately $734,800. This trade represents a 7.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 147,432 shares of company stock worth $2,957,986 in the last ninety days. Insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. R Squared Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $38,000. Values First Advisors Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at $52,000. Van ECK Associates Corp lifted its stake in shares of Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after buying an additional 1,250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock valued at $88,000 after buying an additional 788 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after buying an additional 1,644 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.